SCHEMBL25407146

SCHEMBL25407146

CC(C)(C)OC(=O)N1CCC2(CC1)CCN(c1ccc(Br)c(C(F)F)n1)CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 7/20 0.45
▸ CYP11B2 P19099 1/20 0.44
▸ MAP4K4 O95819 1/20 0.43
▸ KIF18A Q8NI77 1/20 0.42
▸ CYP3A4 P08684 3/20 0.41
▸ CYP2C19 P33261 3/20 0.41
▸ TSHR P16473 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ RET P07949 1/20 0.40
▸ CKS1B P61024 2/20 0.40
▸ SKP1 P63208 2/20 0.40
▸ SKP2 Q13309 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ACACB O00763 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338079 1.00 GPR119 (0.45) GPR119CYP11B2MAP4K4KIF18ACYP3A4
SCHEMBL30480339 0.90 MAP4K4 (0.52) GPR119MAP4K4TSHRRETCKS1B
SCHEMBL25248226 0.90 MAP4K4 (0.52) GPR119MAP4K4TSHRRETCKS1B
SCHEMBL30456054 0.83 USP2 (0.39) CYP3A4CYP2C19TSHRHSD17B10CYP2D6
SCHEMBL25275503 0.83 GPR119 (0.44) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL30455853 0.83 GPR119 (0.44) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL1780700 0.77 RET (0.51) GPR119CYP11B2MAP4K4CYP3A4CYP2C19
SCHEMBL29455974 0.77 RET (0.51) GPR119CYP11B2MAP4K4CYP3A4CYP2C19
SCHEMBL30328017 0.76 HRH3 (0.53) GPR119CYP11B2MAP4K4KIF18ACYP3A4
SCHEMBL27027530 0.75 MAP4K4 (0.55) GPR119MAP4K4RETCKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279001-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-09-07 — — US disclosed
US-20230279001-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-09-07 — — US disclosed
US-20230279001-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-09-07 — — US disclosed
CN-115835911-A Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2023-03-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279001-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE SSB, CNKSR1, UACA GPR119 231/4885CYP11B2 269/4885MAP4K4 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback